Results 141 to 150 of about 22,470,337 (287)

Driving Drugs Deeper: Force‐Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation

Small, EarlyView.
Force‐driven microneedles are presented as active therapeutic microdevices that overcome the diffusion limits of conventional patches. By integrating gas generation, magnetic actuation, cavitation, or iontophoresis, these systems drive payloads deeper into tissue, enabling faster, more controlled delivery and highlighting key design principles and ...
Majed Amini, Phoebe Li, Hamed Shahsavan, Mahla Poudineh   +3 more
wiley   +1 more source

Unusual manifestation of diffuse large B-cell lymphoma [PDF]

Polish Archives of Internal Medicine, 2020
Izabela, Rubisz, Paweł, Gajdzis, Małgorzata, Gajdzis, Radosław, Kaczmarek   +3 more
openaire   +3 more sources

Pancreatic Panniculitis as the First Presentation of Pancreatic Adenocarcinoma

JEADV Clinical Practice, EarlyView.
Claudine Howard‐James, Graham Woods, Ian McDonald   +2 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source

Diffuse Large B-cell Lymphoma of the Testis [PDF]

Mayo Clinic Proceedings, 2016
Rosalind F, Sandell, Lori A, Erickson
openaire   +2 more sources

Thrombocytosis and tumour distribution predict outcome in dogs with hepatocellular carcinoma: A multi‐institutional retrospective analysis

Veterinary Record, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is the most common canine hepatobiliary tumour. This study aimed to determine which criteria influenced outcome of HCC in a modern population of dogs across eight institutions. Methods The medical records of 106 dogs with HCC were retrospectively reviewed.
Emily A. Janik, MacKenzie A. Pellin, Dawn M. Clarke   +2 more
wiley   +1 more source

Primary Diffuse large B-cell lymphoma of spleen: A rare case report

Mediterranean Journal of Hematology and Infectious Diseases, 2014
Primary splenic lymphoma is very rare with an incidence less than 1% and, 22% to 33% of the cases being diffuse large B-cell lymphoma with a relatively favourable prognosis.
Biswajit Dey, Jyotsna Naresh Bharti, Richa Gupta, Nita Khurana, Tejinder Singh, PN Agarwal   +5 more
doaj  

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Chronic intussusception revealing primary diffuse large B-cell lymphoma of the small intestine: A case report. [PDF]

Radiol Case Rep
Lembarki S, El Malki FE, Laamrani FZ, Omor Y, Latib R, Amalik S.   +5 more
europepmc   +1 more source